Rheumatoid Arthritis

Shutterstock_107653352

Rheumatoid arthritis (RA) is a disease mainly defined by its clinical features of chronic inflammation in joints associated with bone and cartilage destruction. RA is a severe burden to patients leading to disability, pain, severe impairment of quality of life, and even life threatening conditions resulting in a significantly enhanced mortality. Therefore the pharmaceutical market for arthritis generates billions of dollars and is constantly increasing over the last decades.

TNF-alpha inhibitors dominate in the clinic as first-line biological agents. The major players in the arthritis drug market include Remicade® (infliximab), Humira® (adalimumab), Enbrel® (etanercept), Cimzia® (certolizumab pegol) and Simponi® (golimumab), while biosimilars of the above as well as new drugs with novel mechanisms of action are under development.

Biomedcode’s unique animal models of human TNF- depended arthritis have offered the first proof of concept for the central role of TNF in the development of human pathology.

Today our rich collection of arthritis mouse models is widely used for the preclinical evaluation of the efficacy of anti-arthritic pharmaceuticals and offer an ideal platform for establishing proof of concept for novel technological advances.